Korabiowska Monika, Brinck Ulrich, Stachura Jerzy, Jawien Jacek, Hasse Frank Michael, Cordon-Cardos Carlos, Fischer Gösta
Institute of Pathology, Reinhard Nieter Hospital, Academic Hospital of the University of Göttingen, Friedrich Paffrath Str. 100, 26389 Wilhelmshaven, Germany.
Anticancer Res. 2006 Mar-Apr;26(2A):1231-5.
The mutations of MLH1 and MSH2 have been reported to be responsible for malignant transformation and tumour progression in several sporadic tumours. Eighty-six primary malignant melanomas with known follow-up were investigated. Point mutations of DNA mismatch repair MLH1 and MSH2 in malignant melanomas were not found. Exon 12 (MSH2) was not present in 26 out of the 86 melanomas and exon 13 (MSH2) was lost in 25 of the tumours. The loss of exon 15 (MLH1) was observed in 22 out of the 86 tumours and the loss of exon 16 (MLH1) in 24 melanomas. The loss of exons correlated strongly with the loss of MLH1 and MSH2 protein expression. In multivariate analysis, including all 4 exons and expressions of MLH1 and MSH2, prognostic significance was found only for loss of exon 12 (MSH2) and loss of exon 15 (MLH1).
据报道,MLH1和MSH2的突变与几种散发性肿瘤的恶性转化和肿瘤进展有关。对86例有已知随访情况的原发性恶性黑色素瘤进行了研究。未在恶性黑色素瘤中发现DNA错配修复基因MLH1和MSH2的点突变。86例黑色素瘤中有26例不存在外显子12(MSH2),25例肿瘤中丢失了外显子13(MSH2)。86例肿瘤中有22例观察到外显子15(MLH1)缺失,24例黑色素瘤中存在外显子16(MLH1)缺失。外显子的缺失与MLH1和MSH2蛋白表达的缺失密切相关。在包括所有4个外显子以及MLH1和MSH2表达的多变量分析中,仅发现外显子